QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-maintains-buy-on-dermata-therapeutics-lowers-price-target-to-6

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target fro...

 dermata-therapeutics-q2-eps-418-misses-379-estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate o...

 dermata-therapeutics-entered-into-atm-agreement-with-hc-wainwright-providing-for-sale-by-co-of-12m-of-its-shares-of-common-stock-from-time-to-time

- Reuters 

 dermata-therapeutics-on-june-4-got-letter-from-nasdaq-that-company-has-regained-compliance-with-minimum-bid-price-requirement

-SEC Filing

Core News & Articles

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnolog...

 dermata-therapeutics-q1-2024-gaap-eps-047-misses-036-estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION